J Addict Med 2021 Feb 5. Epub 2021 Feb 5.
Harvard Medical School, Boston, MA (KH); DC Partnership for HIV/AIDS Progress, Hepatitis Clinical Research Program, Washington, DC (KH, LN, JDM, RS, CG, PM, SK, HM, SK, ESR); Critical Care Medicine Department, National Institutes of Health, Bethesda, MD (KH, LN, JDM, HM); Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, MD (RS, CG, PM, SK, HM, SK, ESR); HIPS, Org., Washington, DC (DS, PB, MJ, RK, DM).
Objective: The ANCHOR program offered buprenorphine treatment to people who inject drugs engaged in hepatitis C (HCV) treatment at a Washington, DC harm reduction organization. This analysis describes the program model and outcomes of the opioid care continuum at 1 year.
Methods: Primary outcomes were initiation of buprenorphine and retention in care, defined by an active buprenorphine prescription at given time points. Read More